Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05970809
Other study ID # CS-SAGA-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2023
Est. completion date September 1, 2024

Study information

Verified date August 2023
Source StimuSIL
Contact Ana I Villalba
Phone +34 647160346
Email ana@stimusil.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this 24-week study is to see if the SAGA-001 device is safe and effective at helping people with male pattern hair loss. Two different device configurations are being explored as part of this study. Device A has novel microneedles, lasers, and additional metal microneedles, while Device B only has novel microneedles and lasers. Participants will receive 12 treatments with either Device A or Device B over the course of 24 weeks. Treatments will be performed on-site every two weeks.


Description:

Participants will have the medical tests or procedures described below: - Subjects will be asked about their previous medical history and current medications. - Brief physical examinations will be performed, including a visual inspection of the scalp. - Questions about medical history (including previous and current medication use) will be asked. - Two types of photos will be taken: 1) "global photos", which are general photos of the subject's scalp, and 2) "macro photos", which are close-up photos of a part of the subject's scalp. - Questions about treatment-related issues or unpleasantness will be asked. - Subjects will be asked to rate the improvement they see in their photos. - Subjects will be asked to rate their satisfaction with the treatment. Participants will also be asked to record changes in medications, changes in medical treatments, and major life changes (such as major dietary changes, exercise changes, changes in life stressors, etc.) in a diary for the duration of treatment. They should also make note of any suspected side effects or issues they believe are related to the treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date September 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender Male
Age group 22 Years to 55 Years
Eligibility Inclusion Criteria: - Subject is willing to sign an informed consent form - Subject is within the age group of 22-55 years (including both ages) - Subject is male - Subject has AGA with a Stage IIa-V Hamilton-Norwood classification - Subject's skin is within Fitzpatrick Skin Types I-IV Exclusion Criteria: - Subjects who have used any formulation or application/administration or type of treatment for disorders of the skin or scalp within 180 days prior to screening, including but not limited to the following treatments: 1. Anti-inflammatory medications, including topical steroids 2. Antifungal 3. Skin, nail, hair rejuvenation supplementation, or IV infusions (includes vitamin, minerals, herbals, etc.) 4. Hair growth shampoos, conditioners, and topicals 5. Topical, dermal or oral minoxidil, finasteride, or dutasteride 6. Hair growth stimulation treatments, i.e. PRP, stem cells, exosomes, growth factors, microneedling, mesotherapy 7. LED or low level laser therapy treatments, ie. laser helmets, laser caps, and laser combs 8. Infrared saunas - Subjects with alopecia other than AGA, such as alopecia areata, alopecia totalis, telogen effluvium, anagen effluvium, and acquired cicatricial alopecia - Subjects with a history of bleeding disorders - Subjects on anticoagulant medications (aspirin, warfarin, heparin) - Subject on autoimmune suppressant medications or suffering autoimmune diseases (e.g. humira) - Subjects with an active infection at the local site - Subjects with keloidal tendencies - Subjects with chronic dermatological conditions affecting the scalp (e.g. eczema, psoriasis, etc.) - Subjects with hepatic or renal disease, epilepsy, or any other major medical illness* - Subjects that have undergone evaluation to rule out other causes of hair loss, because underlying causes (e.g., iron deficiency, lupus, thyroid disease, telogen effluvium, post-pregnancy, polycystic ovary, chemotherapy, etc.) would preclude assessment of performance in an androgenetic alopecia trial - Subjects who are photosensitive or are using photosensitive drugs or topicals. - Subjects who are taking anxiolytics medications - Subjects who have been on hormone inhibitors or on hormone replacement therapy in the last 180 days - Subjects who are at high risk of seizures - Subjects who have a malignancy or a history of malignancies affecting the scalp - Subjects that have undergone hair transplantation, scalp reduction, radiation to the scalp or chemotherapy within their lifetime. - Subjects with current hair weaves, hair extensions, scalp tattoos, or who use occlusive wigs. - Subjects who have used semi-permanent hair products (e.g. color, texturizers or relaxers) within 30 days prior to screening. - Subjects with hair shorter than one-half inch (approximately 1.2 cm). - Subjects who are unable to make regular follow-up visits. - Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative sites, or individuals who are directly affiliated with the study at the investigative sites, or individuals directly affiliated with the study sponsor.

Study Design


Intervention

Device:
SAGA-001 (A)
Use of a novel microneedle and laser device as a treatment for male patten hair loss with additional microwounding.
SAGA-001 (B)
Use of a novel microneedle and laser device as a treatment for male patten hair loss without additional microwounding.

Locations

Country Name City State
Turkey Ankara Bilkent Sehir Hastanesi Dermatoloji Klini Ankara
Turkey Istanbul Üniversitesi Cerrahpasa Tip Fakültesi, Dahili Tip Bilimleri Bölümü Deri ve Zührevi Hastaliklar Ana Bilim Dali Kocamustafa Pasa Istanbul

Sponsors (3)

Lead Sponsor Collaborator
StimuSIL Ankara City Hospital Bilkent, Istanbul University - Cerrahpasa (IUC)

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in terminal hair density Changes in terminal hair density at the 24-week time point compared to baseline will be investigated using a binomial test for one proportion at a one-sided alpha with a 95% exact confidence interval, considering pi = 60%, where pi is the true percentage of responders in the study population. 24 weeks
Primary Change in terminal hair density Changes in terminal hair density at the 16-week time point compared to baseline will be investigated using a binomial test for one proportion at a one-sided alpha with a 95% exact confidence interval, considering pi = 60%, where pi is the true percentage of responders in the study population. 16 weeks
Secondary Change in hair thickness Increases and/or decreases in hair diameter at the 16-week time point compared to baseline will be investigated using a paired t-test at a one-sided alpha and a 95% confidence interval for mean change. 16 weeks
Secondary Change in hair thickness Increases and/or decreases in hair diameter at the 24-week time point compared to baseline will be investigated using a paired t-test at a one-sided alpha and a 95% confidence interval for mean change. 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT02591355 - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment N/A
Withdrawn NCT03852992 - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Phase 2
Recruiting NCT06239207 - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia Phase 2
Completed NCT04945226 - A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Phase 1/Phase 2
Completed NCT01548066 - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Phase 2
Completed NCT01437163 - Treatment of Androgenetic Alopecia in Males and Females N/A
Completed NCT01226459 - Clinical Trial in Females for Female Pattern Hair Loss Phase 3
Recruiting NCT06118866 - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia Phase 2
Completed NCT06149221 - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss N/A
Withdrawn NCT04882969 - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia N/A
Completed NCT01231607 - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Phase 3
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT02729415 - Point-of-Care Adipose-derived Cells for Hair Growth N/A
Completed NCT02279823 - A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Phase 2
Not yet recruiting NCT01227031 - Pharmacogenomic Study of Androgenetic Alopecia N/A
Completed NCT00981461 - Treatment of Androgenetic Alopecia in Females, 9 Beam N/A
Completed NCT01451021 - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Phase 2
Completed NCT00151515 - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Phase 3
Completed NCT03694067 - Androgenetic Alopecia and the JAK-STAT Pathway
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A

External Links